STOCK TITAN

Tango Therapeutics (TNGX) director awarded RSUs and 25,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tango Therapeutics director Lesley Ann Calhoun received new equity awards, increasing her direct stake in the company. She was granted 4,000 shares of Common Stock in the form of restricted stock units and now directly holds 16,500 Common shares after this award.

She was also granted options to purchase 25,000 shares of Common Stock at an exercise price of $20.2200 per share, expiring on June 5, 2036. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, while the options vest in 12 equal monthly installments starting July 5, 2026, in each case subject to her continuous service.

Positive

  • None.

Negative

  • None.
Insider Calhoun Lesley Ann
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 25,000 $0.00 --
Grant/Award Common Stock 4,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 25,000 shares (Direct, null); Common Stock — 16,500 shares (Direct, null)
Footnotes (1)
  1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
RSU grant 4,000 shares Restricted stock units granted June 5, 2026
Shares held after grant 16,500 shares Common Stock directly owned after RSU award
Option grant size 25,000 options Stock Option (Right to Buy) granted June 5, 2026
Option exercise price $20.2200 per share Strike price for 25,000 stock options
Option expiration June 5, 2036 Expiration date of stock options
RSU vesting date Earlier of June 5, 2027 or next AGM Full vesting timing for 4,000 RSUs
Option vesting start July 5, 2026 First of 12 monthly vesting installments
restricted stock units financial
"These shares are represented by restricted stock units (the "RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Each RSU represents a contingent right to receive one share of Common Stock."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
vest financial
"The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
continuous service financial
"subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Calhoun Lesley Ann

(Last)(First)(Middle)
C/O TANGO THERAPEUTICS, INC.,
201 BROOKLINE AVE., SUITE 901

(Street)
BOSTON MASSACHUSETTS 02215

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026A4,000(1)A$016,500D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$20.2206/05/2026A25,000 (2)06/05/2036Common Stock25,000$025,000D
Explanation of Responses:
1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
2. This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Remarks:
Exhibit 24: Power of Attorney
/s/ Julie Fogarty, as attorney-in-fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Tango Therapeutics (TNGX) director Lesley Ann Calhoun receive?

Lesley Ann Calhoun received 4,000 restricted stock units and options for 25,000 shares of Tango Therapeutics Common Stock. The options have a $20.2200 exercise price and expire on June 5, 2036, forming part of her director compensation.

How do the new RSUs for Tango Therapeutics (TNGX) director vest?

The 4,000 RSUs granted to director Lesley Ann Calhoun vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting. Vesting is contingent on her continuous service with Tango Therapeutics through the applicable vesting date.

What is the vesting schedule for Lesley Ann Calhoun’s Tango Therapeutics stock options?

The 25,000 Tango Therapeutics stock options vest and become exercisable in 12 substantially equal monthly installments over one year. The first vesting date is July 5, 2026, and each installment requires Lesley Ann Calhoun to remain in continuous service with the company.

What is the exercise price and expiration date of the new Tango Therapeutics options?

Lesley Ann Calhoun’s newly granted Tango Therapeutics stock options have a $20.2200 per share exercise price. These options expire on June 5, 2036, providing a long-dated opportunity to purchase Common Stock if vesting conditions and exercise are satisfied.

How many Tango Therapeutics shares does Lesley Ann Calhoun hold after these grants?

Following the grant of 4,000 restricted stock units, Lesley Ann Calhoun directly holds 16,500 shares of Tango Therapeutics Common Stock. This figure reflects her direct ownership position reported after the non-derivative stock award acquisition.